Breaking News Instant updates and real-time market news.

RMD

ResMed

$106.78

-0.14 (-0.13%)

, ATHN

Athenahealth

$156.99

-1.31 (-0.83%)

09:09
06/14/18
06/14
09:09
06/14/18
09:09

Brightree announces ereferral integration with athenahealth

Brightree, a wholly-owned subsidiary of ResMed (RMD), announced the release of a new solution that allows home medical equipment providers to digitally receive orders from more than 62,000 providers using athenaClinicals within the athenahealth network (ATHN), the same way doctors have long referred patients to other specialists.

RMD

ResMed

$106.78

-0.14 (-0.13%)

ATHN

Athenahealth

$156.99

-1.31 (-0.83%)

  • 14

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

RMD ResMed
$106.78

-0.14 (-0.13%)

04/04/18
04/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PTC Therapeutics (PTCT) downgraded to Underweight from Equal Weight at Barclays with analyst Gena Wang saying she sees limited upside to 2018 revenue expectations and believes PTC's growth trajectory is fully priced in at current valuation levels. 2. Cloudera (CLDR) downgraded to Neutral from Overweight at JPMorgan and to Hold from Buy at Deutsche Bank. 3. Domino's Pizza (DPZ) downgraded to Hold from Buy at Deutsche Bank with analyst Brett Levy citing valuation. 4. Virtusa (VRTU) downgraded to Hold from Buy at SunTrust with analyst Frank Atkins saying while Virtusa stock has risen 166% since November of 2016, future upside may be more limited. 5. ResMed (RMD) downgraded to Neutral from Buy at Citi with analyst Victor Windeyer citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
04/23/18
UBSW
04/23/18
DOWNGRADE
UBSW
Neutral
ResMed downgraded to Neutral from Buy at UBS
05/30/18
PIPR
05/30/18
NO CHANGE
Target $190
PIPR
Overweight
Inogen recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst JP McKim views the recent pullback in shares of Inogen (INGN) as unwarranted and recommends buying the shares at current levels. The analyst says his firm's survey of 66 home medical equipment providers indicates the shift to portable oxygen concentrators "remains strong." The market remains in the early innings of this conversion and Inogen is the best way to play this thematic trend, McKim tells investors in a research note. The analyst expects ResMed's (RMD) Mobi to launch this year, but does not expect it to be overly impactful to Inogen. Consensus numbers already reflect a deceleration in growth in the second half of 2018 which is unlikely to materialize, McKim contends. He keeps an Overweight rating on Inogen with a $190 price target.
05/31/18
05/31/18
NO CHANGE

Arcturus Therapeutics reinstates founder Joseph Payne as CEO
Arcturus Therapeutics (ARCT) has named Dr. Peter Farrell as Chairman of the Board of Directors of the company. Joseph E. Payne has been reinstated as President and CEO and Dr. Pad Chivukula has been reinstated as Chief Scientific Officer and COO. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (RMD).
ATHN Athenahealth
$156.99

-1.31 (-0.83%)

06/06/18
DBAB
06/06/18
NO CHANGE
Target $170
DBAB
Hold
Athenahealth management changes up likelihood of sale, says Deutsche Bank
Deutsche Bank analyst Glen Santangelo says the management transition announced this morning by Athenahealth increases the likelihood of a company sale. The analyst reiterates his $170 price target on the shares. He keeps a Hold rating on Athenahealth.
06/06/18
PIPR
06/06/18
NO CHANGE
Target $179
PIPR
Overweight
Piper ups Athenahealth target to $179 after strategic alternatives announcement
Piper Jaffray analyst Sean Wieland tells investors that he "never thought" he'd see the day that founder and CEO Jonathan Bush would step away from Athenahealth, which Wieland views as "among the highest quality asset in Health I/T." The analyst, who thinks Athenahealth's presence at the point of care and ability to crowd-source best practices in clinical and financial workflow are unsurpassed, argues that the company is going into the strategic alternatives process "from a vantage point of strength." Wieland raised his price target on Athenahealth shares to $179 from $155 and keeps an Overweight rating on the stock, which is up 4% to $157 in late morning trading following the company's announcement.
06/07/18
LEER
06/07/18
NO CHANGE
Target $160
LEER
Market Perform
Athenahealth price target raised to $160 from $150 at Leerink
Leerink analyst David Larsen raised his price target for Athenahealth to $160 from $150 on the Elliott deal and greater conviction that a transaction will occur. The analyst recently conducted an ambulatory EMR survey and the data showed a significant slow-down in ambulatory EMR and practice management system purchases, with the lowest replacement rate in 5 years, based on his MEDACorp survey work. Larsen believes this market slow-down is why ATHN's bookings declined by about 32% year over year in Q1 and by 16% year over year in 2017. Given the material slow-down in the market he believes that Elliott's offer of $160 per share is a good deal for existing shareholders. The analyst reiterates a Market Perform rating on the shares.
06/12/18
OPCO
06/12/18
NO CHANGE
Target $179
OPCO
Outperform
Athenahealth price target raised to $179 from $158 at Oppenheimer
Oppenheimer analyst Mohan Naidu raised his price target for Athenahealth to $179 from $158, while reiterating an Outperform rating on the shares. The analyst says that the CEO's departure last week makes him believe in the increased likelihood of a transaction. While there is significant discussion about potential suitors, the analyst makes a case for the data-hungry tech companies.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.